The prognostic significance of lymphovascular invasion on biopsy specimens in lung cancer treated with definitive chemoradiotherapy

Clinical Lung Cancer

Volumn 13, Issue 1, 2012, Pages 59-67

  Massabeau, Carole ^a   Filleron, Thomas ^a   Wakil, Georges ^b   Rouquette, Isabelle ^c   Bachaud, Jean Marc ^a   Leguellec, Sophie ^c   Delisle, Marie Bernadette ^c   Toulas, Christine ^a   Mazieres, Julien ^d   Moyal, Elizabeth Cohen Jonathan ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b HÔPITAL CHARLES LEMOYNE   (Canada)

^c CHU RANGUEIL   (France)

^d SERVICE DE PNEUMOLOGIE   (France)

Author keywords

Biopsy; Chemoradiotherapy; Lung cancer; Lymphovascular invasion; Prognostic

Indexed keywords

DOCETAXEL; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; AGED; CANCER INVASION; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL DECISION MAKING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INFORMATION PROCESSING; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LYMPHOVASCULAR INVASION; MAJOR CLINICAL STUDY; MALE; PATHOLOGIST; PATIENT IDENTIFICATION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REVIEW; SURVIVAL TIME;

EID: 84855668578     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.06.011     Document Type: Article

References (58)

1. A. Jemal, R. Siegel, E. Ward Cancer statistics, 2008 CA Cancer J Clin 58 2008 71 96 (Pubitemid 351521864)
2. L.A.G. Ries, M.P. Eisner, C.L. Kosary SEER Cancer Statistics Review 19731997 2000 National Cancer Institute Bethesda, MD
3. K.S. Albain, J.J. Crowley, A.T. Turrisi Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019 J Clin Oncol 20 2002 3454 3460
4. J.R. Jett, W.J. Scott, M.P. Rivera Guidelines on treatment of stage IIIB non-small cell lung cancer Chest 123 suppl 1 2003 221S 225S (Pubitemid 36135719)
5. W.J. Curran Jr Evolving chemoradiation treatment strategies for locally advanced nonsmall-cell lung cancer Oncology (Williston Park) 17 2003 7 14
6. E.E. Vokes, J.E. Herndon 2nd, M.J. Kelley Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B J Clin Oncol 25 2007 1698 1704 (Pubitemid 46797950)
7. N. Hanna, M. Neubauer, C. Yiannoutsos Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology J Clin Oncol 26 2008 5755 5760
8. M.A. Socinski, A.W. Blackstock, J.A. Bogart Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105 J Clin Oncol 26 2008 2457 2463
9. D.R. Gandara, K. Chansky, K.S. Albain Southwest Oncology Group Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504 J Clin Oncol 21 2003 2004 2010 (Pubitemid 46606390)
10. C. Massabeau, I. Rouquette, V. Lauwers-Cances Basic fibroblast growth factor-2/beta3 integrin expression profile: signature of local progression after chemoradiotherapy for patients with locally advanced non-small-cell lung cancer Int J Radiat Oncol Biol Phys 75 2009 696 702
11. P. Goldstraw, J. Crowley, K. Chansky The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours J Thorac Oncol 2 2007 706 714 (Pubitemid 47357522)
12. P. Fournel, G. Robinet, P. Thomas Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced nonsmall-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique- Groupe Francais de Pneumo-Cancerologie NPC 95-01 study J Clin Oncol 23 2005 5910 5917
13. E.A. Eisenhauer, P. Therasse, J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
14. S. Lantuejoul, E. Brambilla What's new in the 2004 WHO classification of the lung tumors? Rev Pneumol Clin 64 2008 187 194 [Review]
15. A. Yoshizawa, N. Motoi, G.J. Riely Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases Mod Pathol 24 2011 653 664
16. P. Zatloukal, L. Petruzelka, M. Zemanova Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study Lung Cancer 46 2004 87 98 (Pubitemid 39201387)
17. K. Furuse, M. Fukuoka, M. Kawahara Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer J Clin Oncol 17 1999 2692 2699 (Pubitemid 29415225)
18. A. Aupérin, C. Le Péchoux, E. Rolland Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer J Clin Oncol 28 2010 2181 2190 [Review]
19. I.H. Lee, J.A. Hayman, M.B. Landrum Treatment recommendations for locally advanced, non-small-cell lung cancer: the influence of physician and patient factors Int J Radiat Oncol Biol Phys 74 2009 1376 1384
20. P. Bonomi, M. Gale, K. Rowland Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment Int J Radiat Oncol Biol Phys 20 1991 247 252
21. T. Berghmans, J.J. Lafitte, J. Thiriaux European Lung Cancer Working Party Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy Lung Cancer 45 2004 339 348 (Pubitemid 39037715)
22. J.M. Bréchot, S. Chevret, M.C. Charpentier Blood vessel and lymphatic vessel invasion in resected nonsmall cell lung carcinoma Correlation with TNM stage and disease free and overall survival Cancer 78 1996 2111 2118 (Pubitemid 26367603)
23. A. Yilmaz, S.S. Duyar, E. Cakir et al. Clinical impact of visceral pleural, lymphovascular and perineural invasion in completely resected non-small cell lung cancer Eur J Cardiothorac Surg 2011 [Epub ahead of print]
24. K. Funai, H. Sugimura, T. Morita Lymphatic vessel invasion is a significant prognostic indicator in stage IA lung adenocarcinoma Ann Surg Oncol 2011
25. M.O. Bodendorf, V. Haas, H.G. Laberke Prognostic value and therapeutic consequences of vascular invasion in non-small cell lung carcinoma Lung Cancer 64 2009 71 78
26. R. Maeda, J. Yoshida, G. Ishii Prognostic impact of intratumoral vascular invasion in non-small cell lung cancer patients Thorax 65 2010 1092 1098
27. K. Miyoshi, S. Moriyama, T. Kunimoto Prognostic impact of intratumoral vessel invasion in completely resected pathologic stage I non-small cell lung cancer J Thorac Cardiovasc Surg 137 2009 429 434
28. T. Tsuchiya, S. Akamine, M. Muraoka Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy Lung Cancer 56 2007 341 348 (Pubitemid 46679089)
29. T.T. Pechet, S.R. Carr, J.E. Collins Arterial invasion predicts early mortality in stage I non-small cell lung cancer Ann Thorac Surg 78 2004 1748 1753 (Pubitemid 39423546)
30. S. Gabor, H. Renner, H. Popper Invasion of blood vessels as significant prognostic factor in radically resected T1-3N0M0 non-small-cell lung cancer Eur J Cardiothorac Surg 25 2004 439 442 (Pubitemid 38340584)
31. R.T. Pu, A.F. Schott, D.E. Sturtz Pathologic features of breast cancer associated with complete response to neoadjuvant chemotherapy: importance of tumor necrosis Am J Surg Pathol 29 2005 354 358 (Pubitemid 40321971)
32. S.E. Pinder, I.O. Ellis, M. Galea Pathological prognostic factors in breast cancer III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up Histopathology 24 1994 41 47 (Pubitemid 24223138)
33. E.A. Rakha, I.O. Ellis An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens J Clin Pathol 60 2007 1300 1306 (Pubitemid 350247244)
34. G.C. Harris, H.E. Denley, S.E. Pinder Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma Am J Surg Pathol 27 2003 11 15 (Pubitemid 36014894)
35. A.P. Meert, M. Paesmans, B. Martin The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis Br J Cancer 87 2002 694 701 (Pubitemid 35178743)
36. G. Gasparini, N. Weidner, P. Bevilacqua Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma J Clin Oncol 12 1994 454 466 (Pubitemid 24079885)
37. B.V. Offersen, P. Pfeiffer, S. Hamilton-Dutoit Patterns of angiogenesis in nonsmall-cell lung carcinoma Cancer 91 2001 1500 1509 (Pubitemid 32319261)
38. C.J. Howlett, E.J. Tweedie, D.K. Driman Use of an elastic stain to show venous invasion in colorectal carcinoma: a simple technique for detection of an important prognostic factor J Clin Pathol 62 2009 1021 1025
39. L.R. Mitchell, J.M. Albert, B. Lu Chemoradiotherapy in locally advanced, unresectable non-small cell lung cancer Rev Recent Clin Trials 4 2009 110 121
40. M.D. Fisher, A. D'Orazio Concurrent chemoradiotherapy followed by consolidation docetaxel in stage IIIB non small-cell lung cancer (SWOG 9504) Clin Lung Cancer 2 2000 25 26
41. D.R. Gandara, K. Chansky, K.S. Albain Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504) Clin Lung Cancer 8 2006 116 121 (Pubitemid 44596753)
42. T. Yano, Y. Morodomi, K. Ito Verification of the newly proposed T category (seventh edition of the tumor, node, and metastasis classification) from a clinicopathological viewpoint in non-small cell lung cancer-special reference to tumor size J Thorac Oncol 5 2010 45 48
43. A. Rossi, S. Ricciardi, P. Maione Pemetrexed in the treatment of advanced non-squamous lung cancer Lung Cancer 66 2009 141 149 [Review]
44. M. Provencio, A. Sánchez, P. Garrido New molecular targeted therapies integrated with radiation therapy in lung cancer Clin Lung Cancer 11 2010 91 97
45. K. Kelly, C. Huang Biological agents in non-small-cell lung cancer: a review of recent advances and clinical results with focus on epidermal growth factor receptor and vascular endothelial growth factor J Thorac Oncol 3 2008 664 673 (Pubitemid 351787316)
46. S. Novello, M. Milella, M. Tiseo Maintenance therapy in NSCLC: why? To whom? Which agent? J Exp Clin Cancer Res 30 2011 50
47. K. Kelly, K. Chansky, L. Gaspar Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023 J Clin Oncol 26 2008 2450 2456
48. R.M. Bremnes, C.Sirera Camps Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood Lung Cancer 51 2006 143 158 (Pubitemid 43144358)
49. B. Bonnesen, H. Pappot, J. Holmstav Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis Lung Cancer 66 2009 314 318
50. R.K. Goudar, G. Vlahovic Hypoxia, angiogenesis, and lung cancer Curr Oncol Rep 10 2008 277 282
51. H. Han, J.F. Silverman, T.S. Santucci Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis Ann Surg Oncol 8 2001 72 79 (Pubitemid 32126827)
52. J.S. Desgrosellier, D.A. Cheresh Integrins in cancer: biological implications and therapeutic opportunities Nat Rev Cancer 10 2010 9 22
53. I. Ader, C. Toulas, F. Dalenc RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death Oncogene 21 2002 5998 6006
54. E. Cohen-Jonathan, C. Toulas, S. Monteil Radioresistance induced by the high molecular forms of the basic fibroblast growth factor is associated with an increased G2 delay and a hyperphosphorylation of p34CDC2 in HeLa cells Cancer Res 57 1997 1364 1370 (Pubitemid 27152563)
55. J.M. Albert, C. Cao, L. Geng Integrin alpha v beta 3 antagonist cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models Int J Radiat Oncol Biol Phys 65 2006 1536 1543 (Pubitemid 44425239)
56. E. Cohen-Jonathan Moyal Angiogenic inhibitors and radiotherapy: from the concept to the clinical trial Cancer Radiother 13 suppl 6-7 2009 562 567 [Review]
57. S. Monferran, N. Skuli, C. Delmas Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB Int J Cancer 123 2008 357 364 (Pubitemid 351842020)
58. R. Stupp, M.E. Hegi, B. Neyns Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma J Clin Oncol 28 2010 2712 2718